



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 June 2017  
EMA/CHMP/ICH/222063/2006  
Committee for Human Medicinal Products

## ICH guideline Q4B Annex 1 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on residue on ignition/sulphated ash Step 5

Transmission to CHMP	June 2006
Transmission to interested parties	June 2006
Deadline for comments	September 2006
Final approval by CHMP	December 2007
Date for coming into operation	June 2008



# ICH guideline Q4B Annex 1 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on residue on ignition/sulphated ash

## Table of contents

<b>1. Introduction .....</b>	<b>3</b>
<b>2. Q4B outcome .....</b>	<b>3</b>
2.1. Analytical procedures.....	3
2.2. Acceptance criteria .....	3
<b>3. Timing of annex implementation .....</b>	<b>3</b>
<b>4. Considerations for implementation.....</b>	<b>3</b>
4.1. General consideration .....	3
4.2. FDA consideration .....	3
4.3. EU consideration .....	4
4.4. MHLW consideration .....	4
4.5. Health Canada consideration.....	4
<b>5. References used for the Q4B evaluation .....</b>	<b>4</b>

## **1. Introduction**

This annex is the result of the Q4B process for Residue on Ignition/Sulphated Ash. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

## **2. Q4B outcome**

### ***2.1. Analytical procedures***

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 20414 Sulphated Ash, JP 2.44 Residue on Ignition Test, and USP <281> Residue on Ignition can be used as interchangeable in the ICH regions given the following:

- Unless otherwise specified in a monograph, an appropriate sample weight is chosen, typically 1-2 g, to result in a level of residue sufficient to be accurately measurable by weight (typically 1 mg). If not specified in the monograph, the appropriate sample weight should be justified, and the sample weight and the acceptance criteria should be specified in the application dossier.
- The muffle furnace should be appropriately calibrated to ensure compliance with regional GMP requirements.

### ***2.2. Acceptance criteria***

The proposed texts evaluated did not contain acceptance criteria.

## **3. Timing of annex implementation**

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing may differ for each region.

## **4. Considerations for implementation**

### ***4.1. General consideration***

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

### ***4.2. FDA consideration***

Based on the recommendation above, and in accordance with the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

### **4.3. EU consideration**

For the European Union, the monographs of the Ph. Eur. have mandatory applicability. Regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter, Sulphated Ash: 20414, on the basis of the declaration of interchangeability made above.

### **4.4. MHLW consideration**

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

### **4.5. Health Canada consideration**

In Canada any of the pharmacopoeial texts cited in Section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

## **5. References used for the Q4B evaluation**

5.1 The PDG Stage 5B sign-off document:

Japanese Pharmacopoeial Forum Volume 14, Number 4 (December 2005). (Note: the PDG cover letter published in this volume was subsequently changed based on Q4B comments.)

5.2 The pharmacopoeial references for Residue on Ignition/Sulphated Ash for this annex are:

5.2.1 European Pharmacopoeia (Ph. Eur.): Supplement 5.6 (official on January 2007) (reference Sulphated Ash 01/2007:20414)

5.2.2 Japanese Pharmacopoeia (JP): 2.44 Residue on Ignition Test as it appears in the JP Fifteenth Edition (March 31, 2006, The Ministry of Health, Labour and Welfare Ministerial Notification No. 285)

5.2.3 United States Pharmacopeia (USP): <281> Residue on Ignition official in USP 29, 2nd Supplement, August 2006.